cabozantinib
exelixis
['cabozantinib', 'urothelial', 'urothelial carcinoma']
asco 2022: cabozantinib fails to offer benefits in metastatic urothelial carcinoma following platinum-based chemotherapy #oncology
Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier.